Peptide research profile

BPC-157

Also known as Body Protection Compound-157 · BPC157 · PL 14736 · Bepecin

A synthetic 15–amino-acid fragment related to a protective protein originally isolated from gastric juice. Most published work is preclinical; human clinical evidence remains limited.

  • Repair & regeneration
  • Immune & inflammation
  • Skin & connective tissue
Preclinical-heavy6 referencesEducational use

Dosing literacy

Dosing & scaling, explained

Human clinical dosing for BPC-157 is not established. The ranges below summarize how amounts are described across the sourced, non-clinical protocols behind this compound — shown so you can recognize and sanity-check a number, not as guidance to follow. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting range200–250 mcg / day
    First 1–2 weeks

    Where sourced protocols commonly begin, to gauge individual response before any increase.

  2. Common range250–400 mcg / day
    Ongoing block

    The most frequently reported day-to-day range in the protocols recorded for this compound.

  3. Higher reported500 mcg / day
    Short blocks, often split AM/PM

    Toward the top of what sourced protocols report. Higher is not established as more effective, and human safety data are limited.

These are drug amounts (mcg). The calculator converts that into syringe units or pen clicks from your vial strength and mixing volume — the dose and the unit count are not the same number.

Schedule literacy

Patterns described in source material

  • Once daily

    A single subcutaneous dose per day is the most commonly reported cadence.

  • Split AM/PM

    Larger daily amounts are sometimes divided into two smaller injections rather than one.

  • Cycled blocks

    Reported use is usually organized in on/off blocks (for example ~4 weeks on, then a break) rather than continuously.

Clinical context

No randomized human trials establish a BPC-157 dose, schedule, or long-term safety profile — every number here comes from non-clinical models or unofficial protocols. As a contrast, some peptides do have trial-tested doses: retatrutide, for example, was studied at 4 mg once weekly in phase-2 research. BPC-157 has nothing equivalent.

Research best practices

Storage, handling and interpretation

Lyophilized powder

Typically stored cold and dry, protected from light, per supplier certificate or CoA instructions.

After reconstitution

Research practice usually refrigerates sterile solutions and avoids freeze–thaw cycles; follow validated lab SOPs.

Handling

Reconstitute gently; do not shake vigorously. Label concentration and date on the vial.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Soft-tissue repair

    Animal and cell studies explore tendon, ligament, and muscle injury models, including Achilles-tendon transection and junction healing.

  • 02

    Gastrointestinal cytoprotection

    Early literature focuses on gut mucosal protection and experimental GI injury models, reflecting the peptide’s gastric origin story.

  • 03

    Angiogenesis & vascular responses

    Preclinical work examines endothelial signaling (including VEGFR2 / nitric-oxide pathways) and collateral vessel responses after injury.

  • 04

    Inflammation & oxidative stress markers

    Rodent studies report changes in selected inflammatory and oxidative-stress markers; these are model-dependent findings, not clinical outcomes.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Review

    Orthopaedic sports-medicine systematic review

    A 2025 systematic review of English-language literature identified predominantly preclinical musculoskeletal studies plus very limited human reporting, and noted the absence of robust clinical safety datasets.

  • Animal

    Tendon and tendon-to-bone models

    Rat Achilles-tendon and tendon-to-bone experiments report improved functional and structural healing markers versus controls in those models; results do not establish human efficacy.

  • In vitro

    Tendon fibroblast outgrowth and migration

    Cell and explant studies describe effects on tendon fibroblast outgrowth, survival under oxidative stress, and migration-related signaling pathways.

  • Human

    Sparse clinical reporting

    Human evidence remains sparse (small pilot / retrospective reports). No large randomized controlled trials establish clinical benefit or a settled safety profile.

Recorded protocol library

Amounts recorded for BPC-157

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Weeks 1–2

    200 mcg

    Sign in for schedule, duration and source context.

  • 02

    Lower recorded

    250 mcg

    Sign in for schedule, duration and source context.

  • 03

    Common reference

    400 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Synthetic pentadecapeptide
Sequence
GEPPPGKPADDAGLV
Amino acids
15
Approx. MW
1419 Da
Origin note
Fragment related to gastric body-protection compound (BPC)

Important limitations

  • Most positive findings come from animal or in-vitro models; translation to humans is unproven.
  • Published clinical data are few, small, and often uncontrolled.
  • Manufacturing quality, identity, and purity of research materials vary widely outside regulated drug development.
  • Optimal dose, route, duration, and long-term safety in humans are not established.
  • Regulatory status and sport anti-doping rules differ by jurisdiction and organization.

Curated sources

6 curated references

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS Journal · 2025 · Review
  2. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal HealingCurrent Reviews in Musculoskeletal Medicine · 2025 · Review
  3. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healingCell and Tissue Research · 2019 · Review
  4. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growthJournal of Orthopaedic Research · 2003 · Animal
  5. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationJournal of Applied Physiology · 2011 · In vitro
  6. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogsFrontiers in Pharmacology · 2022 · Animal

Related profiles